Rachel W. has taken KESIMPTA and has been compensated for her time.
*Typical administration time when ready to inject. Once monthly after 3 weekly starter doses.
Individual results may vary.

Results that speak for themselves.

Over 1800 people aged 18 to 55 with relapsing MS, participated in 2 head-to-head studies that compared KESIMPTA to AUBAGIO® (teriflunomide). In the 1 to 2 years leading up to the studies, all of them had experienced a relapse or saw activity on an MRI scan. Each person received KESIMPTA 20 mg or AUBAGIO 14 mg for up to 30 months. 465 people received KESIMPTA in Study 1, and 481 people in Study 2. 462 people received AUBAGIO in Study 1, and 474 people in Study 2.

465 people received KESIMPTA in Study 1, and 481 people in Study 2. 462 people received AUBAGIO in Study 1, and 474 people in Study 2.

MS, multiple sclerosis.

PROVEN SUPERIOR VS AUBAGIO

Reduced Relapses

Study 1

51 fewer

Study 2

58 fewer

Fewer Active Lesions

(Gd+ T1 lesions)

Study 1

51 fewer

0.01 for KESIMPTA vs
0.46 for AUBAGIO on
average per MRI scan

Study 2

58 fewer

0.03 for KESIMPTA vs
0.52 for AUBAGIO on
average per MRI scan

Fewer New or Enlarging Lesions

(T2 lesions)

Study 1

82 fewer

0.72 for KESIMPTA vs
4.00 for AUBAGIO
per year

Study 2

85 fewer

0.64 for KESIMPTA vs
4.16 for AUBAGIO
per year

Slowed Disability Progression

Studies 1 & 2 combined

34 fewer
32 fewer

*Based on whether disability progression was still present 3 and 6
months after disability symptoms started.

Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging.

Maggie image

quotes Since starting KESIMPTA, I've had fewer relapses, which is really cool. I love seeing that it's really working for me. quotes

– MAGGIE S.

Maggie S. has taken KESIMPTA and has been compensated for her time.
Individual results may vary.

Maggie image

quotes Since starting KESIMPTA, I've had fewer relapses, which is really cool. I love seeing that it's really working for me. quotes

– MAGGIE S.

Maggie S. has taken KESIMPTA and has been compensated for her time.
Individual results may vary.

Check out KESIMPTA
experiences.

SEE PATIENT STORIES

Check out the safety
profile.

GET THE DETAILS
email

Looking for help navigating life with RMS?

Let us bring you personalized resources.
Sign Up

email

Looking for help navigating
life with RMS?

Let us bring you
personalized resources.

Sign Up

phone

Pay as little as $0 copay† & enroll in the
Alongside™ KESIMPTA Support Program.

Learn More

phone

Pay as little as $0 copay† &
enroll in the Alongside™
KESIMPTA Support Program.

Learn More

RMS, relapsing multiple sclerosis.

†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.

+

-

IMPORTANT SAFETY INFORMATION

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.

What is the most important information I should know about KESIMPTA?

INDICATION

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

IMPORTANT SAFETY INFORMATION & INDICATION

INDICATION

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

IMPORTANT SAFETY INFORMATION

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

  • Infections. Serious infections, which can be life-threatening or cause death, can happen during treatment with KESIMPTA. If you have an active infection, your health care provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.

INDICATION

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

  • HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.

  • Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.

  • Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

  • Have or think you have an infection including HBV or PML.

  • Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.

  • Have had a recent vaccination or are scheduled to receive any vaccinations.

    • You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.

    • Whenever possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with KESIMPTA.

    • Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.

  • Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.

  • Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use KESIMPTA?

See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.

  • Use KESIMPTA exactly as your HCP tells you to use it.

  • Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.

  • Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.

KESIMPTA may cause serious side effects including:

  • Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms:

    • at or near the injection site: redness of the skin, swelling, itching, and pain or

    • that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills, and tiredness.

  • Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.

The most common side effects of KESIMPTA include:

  • Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.

  • Headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information including Medication Guide.

KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.

ALONGSIDE and the ALONGSIDE logo are trademarks of Novartis AG.

AUBAGIO is a registered trademark of Genzyme, a Sanofi company.

Please see each product's respective PI for additional information including indication, dosing, and safety.